As an office of the executive branch, the Department of Health and Human Services “does not have the authority” to implement ...

The safety update for Vyvgart rattled argenx’s shares on Monday, a reaction that analysts at William Blair said was “overdone ...

Kennedy wants to expand the injury compensation program to include COVID-19 vaccines, while also stretching the “statute of ...

California’s life sciences manufacturing jobs dipped 3.7% in 2024, according to a new Biocom California report. Still, ...

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

In this episode presented by IQVIA, BioSpace's head of insights Lori Ellis discusses the FDA's first draft guidance for AI in ...

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...